GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IQVIA Holdings Inc (BSP:I1QV34) » Definitions » Cyclically Adjusted PS Ratio

IQVIA Holdings (BSP:I1QV34) Cyclically Adjusted PS Ratio : 4.04 (As of Apr. 30, 2024)


View and export this data going back to 2020. Start your Free Trial

What is IQVIA Holdings Cyclically Adjusted PS Ratio?

As of today (2024-04-30), IQVIA Holdings's current share price is R$303.00. IQVIA Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was R$75.01. IQVIA Holdings's Cyclically Adjusted PS Ratio for today is 4.04.

The historical rank and industry rank for IQVIA Holdings's Cyclically Adjusted PS Ratio or its related term are showing as below:

BSP:I1QV34' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.73   Med: 3.59   Max: 5.17
Current: 3.55

During the past years, IQVIA Holdings's highest Cyclically Adjusted PS Ratio was 5.17. The lowest was 2.73. And the median was 3.59.

BSP:I1QV34's Cyclically Adjusted PS Ratio is ranked worse than
63.97% of 136 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.235 vs BSP:I1QV34: 3.55

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

IQVIA Holdings's adjusted revenue per share data for the three months ended in Dec. 2023 was R$25.681. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is R$75.01 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


IQVIA Holdings Cyclically Adjusted PS Ratio Historical Data

The historical data trend for IQVIA Holdings's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IQVIA Holdings Cyclically Adjusted PS Ratio Chart

IQVIA Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 5.11 3.34 3.48

IQVIA Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.34 3.15 3.48 2.99 3.48

Competitive Comparison of IQVIA Holdings's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, IQVIA Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IQVIA Holdings's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IQVIA Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where IQVIA Holdings's Cyclically Adjusted PS Ratio falls into.



IQVIA Holdings Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

IQVIA Holdings's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=303.00/75.01
=4.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IQVIA Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, IQVIA Holdings's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=25.681/129.4194*129.4194
=25.681

Current CPI (Dec. 2023) = 129.4194.

IQVIA Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 5.714 99.695 7.418
201406 5.677 100.560 7.306
201409 6.264 100.428 8.072
201412 7.242 99.070 9.461
201503 8.304 99.621 10.788
201506 8.875 100.684 11.408
201509 11.092 100.392 14.299
201512 11.991 99.792 15.551
201603 11.347 100.470 14.616
201606 10.939 101.688 13.922
201609 10.045 101.861 12.763
201612 8.104 101.863 10.296
201703 7.855 102.862 9.883
201706 8.728 103.349 10.930
201709 8.818 104.136 10.959
201712 9.695 104.011 12.063
201803 9.910 105.290 12.181
201806 11.529 106.317 14.034
201809 12.884 106.507 15.656
201812 12.792 105.998 15.619
201903 12.777 107.251 15.418
201906 13.166 108.070 15.767
201909 14.330 108.329 17.120
201912 15.087 108.420 18.009
202003 17.190 108.902 20.429
202006 17.129 108.767 20.381
202009 19.298 109.815 22.743
202012 21.719 109.897 25.577
202103 24.641 111.754 28.536
202106 22.175 114.631 25.036
202109 22.915 115.734 25.625
202112 26.361 117.630 29.003
202203 22.952 121.301 24.488
202206 23.383 125.017 24.206
202209 24.654 125.227 25.479
202212 26.011 125.222 26.883
202303 25.214 127.348 25.624
202306 24.230 128.729 24.360
202309 24.867 129.860 24.783
202312 25.681 129.419 25.681

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


IQVIA Holdings  (BSP:I1QV34) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


IQVIA Holdings Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of IQVIA Holdings's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


IQVIA Holdings (BSP:I1QV34) Business Description

Traded in Other Exchanges
Address
2400 Ellis Road, Durham, NC, USA, 27703
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.

IQVIA Holdings (BSP:I1QV34) Headlines

No Headlines